Malaria is a killer and the search for a potent vaccine continues. However thanks to some breakthroughs which all started from Sanaria researchers reportedly creating the world’s first malaria vaccine, renowned drugmaker GlaxoSmithKline may have something to offer as well soon.
With their own large-scale Phase III trial, the UK drugmaker was reportedly able to reduce malaria cases significantly in African children across seven countries over the past 18 months, thus giving hope that a safe and approved vaccine may yet be out by 2015.
Malaria is a serious illness that affects 216 million people around the world, and kills 650,000 every year. It occurs in areas with large mosquito populations and is transmitted by a parasite carried by the insects. Over 3.3 billion people worldwide live in areas that put them at risk of contracting the disease.